41135-98-2

Usage

Uses

Used in Pharmaceutical Industry:
14-hydroxymorphine-6-one is used as an intermediate in the synthesis of various pharmaceutical compounds for its role as a metabolite of Morphine. Its chemical properties make it a valuable component in the development of new drugs with potential pain-relieving and therapeutic effects.
Used in Research and Development:
In the field of scientific research, 14-hydroxymorphine-6-one is utilized as a key substance for studying the metabolic pathways of Morphine and understanding its effects on the human body. This knowledge can contribute to the advancement of drug design and the creation of more effective medications.
Used in Quality Control and Analysis:
14-hydroxymorphine-6-one is also employed in the quality control and analysis of Morphine and its derivatives. Its presence in samples can be used to verify the purity and authenticity of these substances, ensuring the safety and efficacy of medications containing Morphine.

Upstream product

• 115-37-7 thebaine 
• 1234788-73-8 oxymorphinone-N-oxide hydrochloride 
• 467-04-9 oripavine 
• 23185-97-9 8β,14-dihydroxy-7,8-dihydrocodeinone 
• 508-54-3 14-hydroxycodeinone 
• 57-27-2 MORPHIN 
• 109440-85-9 4,5α-epoxy-3,8β,14-trihydroxy-17-methyl-morphinan-6-one 

Downstream Products

• 76-41-5 oxymorphone 
• 64643-76-1 4,5α-epoxy-3,14-diacetoxy-6-oxo-17-methylmorphinan 
• 20594-83-6 nalbuphine 
• 16590-41-3 Naltrexone 
• 131575-15-0 3-(Benzyloxy)-7,8-didehydro-4,5α-epoxy-14β-methoxy-17-methylmorphinan-6-one 
• 1357076-49-3 3-O-benzyl-14-O-but-2-enyloxymorphinone 
• 26988-26-1 3-O-benzyl-14-hydroxymorphinone 
• 33522-95-1 noroxymorphone 
• 465-65-6 Naloxone 
• 84116-46-1 7,8-didehydro-4,5α-epoxymorphinan-6-keto-3,14-diol 
• 862190-33-8 6-O-tosyl-14-hydroxy-3-deoxymorphine 
• 3371-56-0 6α-oxymorphol 

Relevant academic research and scientific papers

AN IMPROVED PROCESS FOR O-DEMETHYLATING METHOXY SUBSTITUTED MORPHINAN-6-ONE DERIVATIVES USING BORON-BASED COMPLEXES

The present invention discloses an improved process for O-demethylation of methoxy-substituted morphinan-6-one derivatives using boron-based complex as a demethylating boron complex in an inert reaction solvent.

Design and Development of Pd-Catalyzed Aerobic N-Demethylation Strategies for the Synthesis of Noroxymorphone in Continuous Flow Mode

Strategies for the generation of noroxymorphone from 14-hydroxymorphinone are presented. Noroxymorphone is the key intermediate in the synthesis of various opioid antagonists, including naloxone, naltrexone, and nalmefene, as well as mixed agonists-antagonists such as nalbuphine. The transformation requires removal of the N-methyl group from the naturally occurring opiates and double-bond hydrogenation. The pivotal reaction step thereby is an N-methyl oxidation with colloidal palladium(0) as catalyst and pure oxygen as terminal oxidant. The reaction produces a 1,3-oxazolidine intermediate, which can be readily hydrolyzed to the corresponding secondary amine. Different reaction sequences and the use of various phenol protecting groups were explored. The most direct route consumes only H2, O2, and H2O as stoichiometric reagents and produces only H2O as a byproduct. Challenges inherent to gas/liquid reactions with oxygen as oxidant have been addressed by developing a continuous flow process.

PROCESS FOR IMPROVED OXYMORPHONE SYNTHESIS

Processes for preparing oxymorphone are provided. Said processes encompass a step which is a hydrogenation of an 14-hydroxymorphinone salt in the presence of trifluoroacetic acid and/or a glycol.

PROCESS FOR OBTAINING 3,14-DIACETYLOXYMORPHONE FROM ORIPAVINE

The present invention relates to a new process for obtaining 3,14-diacetyloxymorphone from oripavine, a process to transform the obtained 3,14-diacetyloxymorphone into a noroxymorphone and a process to transform said noroxymorphone into naloxone, naltrexone, nalbuphine, nalfurafine or nalmefene.

Synthesis of Nororipavine and Noroxymorphone via N- and O-Demethylation of Iron Tricarbonyl Complex of Thebaine

Thebaine was converted into its iron tricarbonyl complex, which underwent successive N- and O-demethylation with BrCN and BBr3, respectively. Decomplexation of the iron tricarbonyl moiety was accomplished with ammonium cerium(IV) nitrate (CAN) and base-catalyzed hydrolysis furnished nororipavine. When excess CAN was used the methoxydiene unit was converted into its C-14 nitrate that on hydrogenation and further hydrolysis furnished noroxymorphone. Full experimental and spectral data are provided for all key compounds.

PROCESS FOR THE PREPARATION OF OXYMORPHONE FREEBASE

The present invention is directed to a process for the preparation oxymorphone freebase, comprising hydrogenation of 14-hydroxymorphinone in DMF, to yield oxymorphone freebase, preferably oxymorphone freebase of improved appearance, purity and / or yield. The present invention is further directed to oxymorphone freebase with improved impurity profile. The present invention is further directed to an HPLC or UPLC system/method for analysis of opioid compounds.

Processes for Making Opioids Including 14-Hydroxycodeinone and 14-hydroxymorphinone

Improved processes for making opioid products having low impurity levels including making 14-hydroxycodeinone and 14-hydroxymorphinone from thebaine and oripavine, respectively.

PROCESS FOR IMPROVED OXYMORPHONE SYNTHESIS

Processes for preparing oxymorphone are provided. Said processes encompass a step which is a hydrogenation of an 14-hydroxymorphinone salt in the presence of trifluoroacetic acid and/or a glycol.

O-DEMETHYLATING PROCESS OF METHOXY SUBSTITUTED MORPHINAN-6-ONE DERIVATIVES

The present invention relates to an improved process for O-demethylating methoxy substituted morphinan-6-one derivatives using AlCl3 as a demethylating agent in a reaction-inert solvent having a water content ranging from 0.1 %wt to 0.8 %wt.10

PROCESS FOR IMPROVED OPIOID SYNTHESIS

Compounds and compositions for use as starting materials or intermediate materials in the preparation of opioids including, e.g., oxymorphone base and/or an oxymorphone salt; processes for preparing these compounds and compositions; uses of these compounds and compositions in the preparation of APIs and pharmaceutical dosage forms; and uses of said APIs and pharmaceutical dosage forms in the treatment of medical conditions.